D. Hargreaves

发表

Discovery and optimization of covalent Bcl-xL antagonists.

H. Mukherjee, Nancy Su, Matthew A. Belmonte, 2019, Bioorganic & medicinal chemistry letters.

Structural and Functional Analysis of the Kid Toxin Protein from E . coli Plasmid

R. Boelens, J. Rafferty, D. Hargreaves, 2002 .

Crystallization of E. coli RuvA gives insights into the symmetry of a Holliday junction/protein complex.

R. G. Lloyd, D. Rice, J. Rafferty, 1997, Acta crystallographica. Section D, Biological crystallography.

Analysis of crystallization data in the Protein Data Bank

Simon E. M. O'Keefe, D. Hargreaves, Julie Wilson, 2015, Acta crystallographica. Section F, Structural biology communications.

Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains.

A. Parker, D. Hargreaves, R. Pauptit, 2007, Journal of molecular biology.

Structure of IL-17A in complex with a potent, fully human neutralizing antibody.

S. Tuske, Y. Hamuro, D. Hargreaves, 2009, Journal of molecular biology.

Development of a novel BCL6 PROTAC to provide insight into small molecule targeting of BCL6

David M. Wilson, Qing Cao, M. Waring, 2018 .

Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.

David M. Wilson, Qing Cao, M. Waring, 2018, ACS chemical biology.

Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.

Matthew Grist, C. Chuaqui, Qing Cao, 2017, Journal of medicinal chemistry.

Predicting the Effect of Chemical Factors on the pH of Crystallization Trials

J. Newman, D. Hargreaves, Julie Wilson, 2020, iScience.

Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance.

Paul D. Smith, Michal Bista, D. Hargreaves, 2021, Journal of medicinal chemistry.

Mechanistic insights into the rational design of masked antibodies

S. Jackson, D. Hargreaves, G. Browne, 2022, mAbs.

Virtual Screening in the Cloud Identifies Potent and Selective ROS1 Kinase Inhibitors

J. Sadowski, D. Hargreaves, James S. Scott, 2022, J. Chem. Inf. Model..

Crystallization and preliminary X-ray crystallographic studies on the parD-encoded protein Kid from Escherichia coli plasmid R1.

D. Rice, R. Boelens, J. Rafferty, 2002, Acta crystallographica. Section D, Biological crystallography.

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

J. A. Hendricks, David M. Wilson, S. Kazmirski, 2018, Nature Communications.

Predicting the Effect of Chemical Factors on the pH of Crystallisation Trials

J. Newman, D. Hargreaves, Julie Wilson, 2020 .

Using isoelectric point to determine the pH for initial protein crystallization trials

Simon O'Keefe, Julie Wilson, Jobie Kirkwood, 2015, Bioinform..

A high-throughput colourimetric method for the determination of pH in crystallization screens.

Simon E. M. O'Keefe, D. Hargreaves, Julie Wilson, 2014, Acta crystallographica. Section D, Biological crystallography.

Engineering a high-affinity anti-IL-15 antibody: crystal structure reveals an α-helix in VH CDR3 as key component of paratope.

D. Hargreaves, R. Pauptit, Malcolm A. Anderson, 2011, Journal of molecular biology.

Selective non zinc binding inhibitors of MMP13.

D. Hargreaves, P. Macfaul, Galith Karoutchi, 2011, Bioorganic & medicinal chemistry letters.

Novel acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with reduced acyl glucuronide liability: the discovery of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid (AZD8329).

Martin J Packer, Nidhal Selmi, Andrew Stocker, 2012, Journal of medicinal chemistry.

Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors.

Anthony D. Keefe, Christoph E. Dumelin, S. Kazmirski, 2017, ACS medicinal chemistry letters.

Non-cytotoxic variants of the Kid protein that retain their auto-regulatory activity.

J. Rafferty, D. Hargreaves, M. Lemonnier, 2003, Plasmid.

Crystal structure of E.coli RuvA with bound DNA Holliday junction at 6 Å resolution

R. G. Lloyd, Peter J. Artymiuk, David W. Rice, 1998, Nature Structural Biology.

R. G. Lloyd, D. Rice, P. Artymiuk, 1998, Journal of molecular biology.

Crystal Structure of DNA Recombination Protein RuvA and a Model for Its Binding to the Holliday Junction

R. G. Lloyd, P J Artymiuk, D W Rice, 1996, Science.

Purification, crystallization and preliminary crystallographic analysis of phosphoglucose isomerase from the hyperthermophilic archaeon Pyrococcus furiosus.

Jasper Akerboom, D. Rice, P. Baker, 2003, Acta crystallographica. Section D, Biological crystallography.

Computational Design of Epitope-Specific Functional Antibodies.

Yanay Ofran, Guy Nimrod, Sharon Fischman, 2018, Cell reports.

Crystallization of Escherichia coli RuvA complexed with a synthetic Holliday junction.

R. G. Lloyd, D. Rice, J. Rafferty, 1999, Acta crystallographica. Section D, Biological crystallography.

Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017).

Martin J Packer, Nidhal Selmi, David Hargreaves, 2012, Journal of medicinal chemistry.

Structural and functional analysis of the kid toxin protein from E. coli plasmid R1.

R. Boelens, J. Rafferty, D. Hargreaves, 2002, Structure.

Capecitabine monotherapy in metastatic colorectal cancer.

J. Nguyen-Van-Tam, D. Hargreaves, C. Twelves, 2001, The Lancet. Oncology.

Antibody fragments structurally enable a drug-discovery campaign on the cancer target Mcl-1

S. Kazmirski, D. Hargreaves, P. Rawlins, 2019, Acta crystallographica. Section D, Structural biology.

Abstract 4451: Evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation

Paul D. Smith, D. Hargreaves, Matthew J. Martin, 2019, Cancer Chemistry.

Matched triplicate design sets in the optimisation of glucokinase activators – maximising medicinal chemistry information content

Michael J. Waring, David Hargreaves, Nathaniel G. Martin, 2013 .

D. Hargreaves, D. Ogg, James S. Scott, 2012, Journal of medicinal chemistry.

Not getting in too deep: A practical deep learning approach to routine crystallisation image classification

Chen Qian, D. Hargreaves, Julie Wilson, 2022, bioRxiv.

Design of rigid protein–protein interaction inhibitors enables targeting of undruggable Mcl-1

D. Hargreaves, E. Chiarparin, S. Degorce, 2023, Proceedings of the National Academy of Sciences of the United States of America.

Abstract DDT01-02: AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers

S. Kazmirski, J. Tyner, D. Hargreaves, 2017 .